REPROGRAM: REsilience PROmotion with GeRoprotectors: AssessMent of biological effect: Rationale and protocol for a trial of biological effect.
A major clinical trial is now testing compounds that slow cellular aging, bringing senescence biology from lab to human patients.
The REPROGRAM trial protocol describes a clinical study evaluating geroprotector compounds (agents targeting cellular senescence) for their ability to slow biological aging in older adults, using multi-omics biomarker endpoints. This protocol publication marks a significant milestone in translating aging biology into clinical interventions.
What the study was
- Study design
- Clinical trial protocol
- Population
- Older adults enrolled in a geroprotector intervention trial (protocol publication)
- Category
- Prevention
- Maturity
- Exploratory
- Journal
- PLoS One
Why it surfaced
Protocol paper for a novel geroprotector clinical trial — notable for the aging/longevity watchlist as it signals active clinical development of senolytic/senomorphic interventions. Design score 0 as protocol only (no results).
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.